5Arteaga C. Targeting HER1/EGFR: A molecular approach to cancer therapy[J]. Semin Oncol, 2003,30(Suppl 7) : 3-14.
6Arteaga C,Moulder S L,Yakes F M. HER (erbB) Tyrosine kinase Inhibitors in the treatment of breast cancer[J]. Semin Oncol,2002,29(Suppl 11) : 4-10.
7Kim M A, Jung E J, Lee H S,et al. Evaluation of HER-2/neu gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction[J]. Hum Pathol, 2007, 38 (9): 1386- 1393.
8Dandachi N, Dietze O, Hauser Kronberger C. Evaluation of the clinical significance of HER 2/neu amplification by ehromogenic in situ hybridisation in patients with primary breast cancer[J].Anticancer Res,2004,24(4) :2401-2406.
9Hauser-Kronberger C, Dandachi N. Comparison of chromogenic in situ hybridization with other methodologies for HER-2/neu status assessment in breast cancer[J]. J Mol Histol, 2004,35 (6) :647-653.
10Wixom C R, Alhers E A, Weidner N. HER--2/neu amplification: correlation of chromogenic in situ hybridization with immu nohistochemistry and fluorescence in situ hybridization[J]. Appl Immunohistochem Mol Morphol, 2004,12(3):248-251.
3Gordon MA, Gundacker HM, Benedetti J, Macdon- ald JS, Baranda JC, Levin WJ, Blanke CD, Elatre W, Weng P, Zhou JY, Lenz HJ, Press MF. Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol ,2013, 24:1754-1761 [PMID: 23524864 DOI: 10.1093/an- nonc/mdt1061.
4Hengartner MO. The biochemistry of apoptosis. Na- ture ,2000, 407:770-776 [PMID: 11048727].
5Zyss D, Montcourrier P, Vidal B, Anguille C, M6rezgue F, Sahuquet A, Mangeat PH, Coopman PJ. The Syk tyrosine kinase localizes to the centro- somes and negatively affects mitotic progression. Cancer Res ,2005, 65:10872-10880 [PMID: 16322234 DOI: 10.1158/0008-5472.CAN-05-1270].
6Sada K, Takano T, Yanagi S, Yamamura H. Struc- ture and function of Syk protein-tyrosine kinase. J 8iochem ,2001, 130:177-186 [PMID: 11481033 DOI: 10.1093/oxfordjournals.jbchem.a002970].
7Mahabeleshwar GH, Kundu GC. Syk, a protein- tyrosine kinase, suppresses the cell motility and nuclear factor kappa B-mediated secretion of uro- kinase type plasminogen activator by inhibiting the phosphatidylinositol 3'-kinase activity in breast cancer cells. J Biol Chem ,2003, 278:6209-6221 [PMID: 12477728].
8Toyama T, lwase H, Yamashita H, Hara Y, Omoto Y, Sugiura H, Zhang Z, Fujii Y. Reduced expres- sion of the Syk gene is correlated with poor prognosis in human breast cancer. Cancer Lett ,2003, 189:97-102 [PMID: 12445683 DOI: 10.1016/ S0304-3835(02)00463-9].
9Ross JS, McKenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest ,2001, 19:554-568 [PMID: 11458821].
10Siddiqa A, Long LM, Li L, Marciniak RA, Kazhdan I. Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) sig- nalling pathways. BMC Cancer ,2008, 8:129 IPMID: 18454859 DOI: 10.1186/1471-2407-8-129].
